Podcast: A Bright future for Biomanufacturing.
Andrew Badrot, Founder and CEO of CMS Pharma and former Vice President of Strategy at Lonza discusses the outsourced biologics manufacturing market with our Healthcare Analyst, George Green, in this special telepodcast interview…
Themed upon the new release of our Contract Biomanufacturing Report, this short interview will provide you with insights into:
- The changing landscape of the biomanufacturing industry.
How this sector is becoming a key driver of pharmaceutical drug sales, with a number of recent late-stage clinical trial approvals contributing to growth rates above 7%.
- Drivers and resistors of biomanufacturing.
How new technologies, orphan drugs and improved methods of production are fuelling productivity, while reduced regulatory scrutiny surrounding biologics drugs approval suggest this growth is likely to be sustained in the long-term. However, resistors to growth are also present – with competition from emerging markets and lower technological investment required to introduce single-use manufacturing systems.
This podcast is based on our new report ‘The Contract Biomanufacturing Outlook to 2017′.